DURHAM, N.C., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced in vitro activity of its investigational antiviral brincidofovir (BCV) against the Ebola virus following testing at the Viral Special Pathogens Branch of the US Centers for Disease Control and Prevention (CDC) and the US National Institutes of Health (NIH). Additional assessments of BCV in animal model studies are being conducted through the CDC and NIH.
The company will be attending the World Health Organization's (WHO) two-day conference on September 4-5, 2014 in Geneva, Switzerland. This is the second conference to discuss potential therapies and vaccines that may be appropriate for further study in the current Ebola virus outbreak in Western Africa. On August 11, 2014, WHO convened scientific and medical experts and ethicists from the affected countries to consider the potential use of unapproved therapies and vaccines. As no medicines have received regulatory approval for Ebola virus infection, important topics include clinical trial design, ethics, regulatory approaches and data collection. The conference attendees will be considering available data on investigational agents; for brincidofovir, important considerations include the large safety database of over 1000 patients, the ongoing Phase 3 trials in cytomegalovirus and adenovirus, potential risks and benefits, and the immediate availability of tablets which are stable at room temperature and do not require cold storage.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary technology has given rise to brincidofovir (BCV, CMX001), a clinical-stage nucleotide analog lipid-conjugate, which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Chimerix is currently enrolling SUPPRESS, a Phase 3 study of brincidofovir for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant (HCT) recipients. In addition, Chimerix is enrolling the pilot portion of the Phase 3 AdVise trial of brincidofovir for treatment of adenovirus (AdV) infection. Chimerix is also working with BARDA to develop brincidofovir as a medical countermeasure against smallpox. For further information, please visit Chimerix's website, www.chimerix.com.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Chimerix's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q, its most recently filed Current Reports on Form 8-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Chimerix undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. CONTACT: Joseph T. Schepers Executive Director, Investor Relations and Corporate Communications email@example.com 919-287-4125
Hey, check out all the research scientist jobs. Post your resume today!